Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trial

Palisade Bio

Palisade Bio

PALI

0.00
  • Palisade Bio won FDA clearance of an IND for PALI-2108, enabling a global Phase 2 ulcerative colitis study.
  • ASCENTRA-UC targets up to 204 patients in North America and Europe; first enrollment expected in H2 2026.
  • Primary efficacy readout is slated for H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED9753928) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.